Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions. Its news flow centers on the progress of its lead investigational product, laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors.
On this page, readers can follow LGVN news related to key clinical programs in hypoplastic left heart syndrome (HLHS), mild Alzheimer’s disease, pediatric dilated cardiomyopathy (DCM), and aging-related frailty. Company announcements highlight milestones such as pivotal Phase 2b trial enrollment in HLHS (ELPIS II), Phase 2a data in Alzheimer’s disease from the CLEAR MIND study, and regulatory interactions including FDA designations like Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT).
Longeveron’s news also covers intellectual property developments, including U.S. and Canadian patents for the use of its proprietary mesenchymal stem cells in aging-related frailty, non-ischemic dilated cardiomyopathy, and female sexual dysfunction. Scientific and medical conference activity, such as poster presentations at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and participation in cardiovascular clinical trial forums, provides additional insight into how the company positions laromestrocel within neurodegenerative and cardiovascular research.
Investors and observers can use this LGVN news feed to track clinical trial updates, patent grants, financing transactions disclosed in press releases, and other corporate developments that Longeveron reports through GlobeNewswire and SEC-related communications.
Longeveron (NASDAQ: LGVN) reported 2025 results and a business update on March 17, 2026. Revenues fell 50% to $1.2M; net loss widened to $22.7M. The company closed an initial $15M private placement (up to $30M) and expects pivotal Phase 2b ELPIS II HLHS topline results in Q3 2026.
Management plans partnering strategies, expects a potential BLA path for HLHS if ELPIS II is successful, and projects cash runway into Q4 2026 after the transaction.
Longeveron (NASDAQ: LGVN) will report 2025 full-year financial results and provide a business update on Tuesday, March 17, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. An archived replay will be available on the company website under Events & Presentations.
Longeveron (NASDAQ: LGVN) closed an initial tranche of a private placement on March 11, 2026, raising approximately $15 million upfront, with eligibility for an additional ~$15 million tied to milestone conditions from its Phase 2b ELPIS II HLHS trial. The financing was priced at-the-market under Nasdaq rules and led by Coastlands Capital with participation from Janus Henderson and other healthcare funds. The company issued 6,013,384 Class A shares at $0.52 and Series A non-voting convertible preferred shares convertible into 22,832,770 Class A shares at $0.52. Net proceeds are expected to extend the cash runway into 4Q26, past the anticipated 3Q26 topline readout, and the company sold investors rights to 50% of net proceeds from any future Rare Pediatric Disease Priority Review Voucher receipt for its laromestrocel HLHS program.
Longeveron (NASDAQ: LGVN) entered a private placement expected to raise up to $30 million in gross proceeds, with an initial closing of approximately $15 million priced at-the-market under Nasdaq rules.
Initial proceeds fund operations into 4Q2026, past anticipated pivotal Phase 2b ELPIS II HLHS topline data in 3Q2026. The financing includes Class A shares and Series A non-voting convertible preferred shares convertible at $0.52, and a contingent second tranche tied to trial milestones and share price.
Longeveron (NASDAQ: LGVN) reported Phase 2b results published in Cell Stem Cell showing intravenous laromestrocel improved physical condition in 148 ambulatory patients with age-related frailty versus placebo. 6-minute walk test (6MWT) increased by 63.4m at month 9 (95% CI: 17.1–109.6m; p=0.0077). Findings include dose-response signals and a potential TIE-2 biomarker for responsiveness.
Longeveron (NASDAQ: LGVN) appointed Stephen H. Willard as CEO, effective February 11, 2026, replacing interim CEO Than Powell who will assist the transition and continue business development work.
The company is focused on top-line Phase 2b HLHS results expected in Q3 2026; FDA guidance indicated a successful trial could serve as a pivotal study for a BLA.
Longeveron (NASDAQ: LGVN) applauds Congress passing the Mikaela Naylon Give Kids a Chance Act, which reauthorizes the Rare Pediatric Disease Priority Review Voucher (PPRV) Program and extends voucher eligibility for medicines approved by the FDA before September 30, 2029.
The company noted FDA Rare Pediatric Disease, Orphan Drug and Fast Track designations for its laromestrocel program in Hypoplastic Left Heart Syndrome (HLHS). The Phase 2b ELPIS II trial enrolled 40 pediatric patients at 12 centers, with top-line results anticipated in Q3 2026. Since 2024, PRVs have traded for $150–200 million each.
Longeveron (NASDAQ: LGVN) announced that the Japan Patent Office granted Japan Patent No. 2022-563984 for potency assay methods to assess human mesenchymal stem cells (MSCs), with protection through April 20, 2041 assuming annuity payments.
The patent expands Longeveron's international IP to 33 issued patents and supports development of laromestrocel (Lomecel-B). A pivotal Phase 2b trial in Hypoplastic Left Heart Syndrome (HLHS) is ongoing, with results expected in Q3 2026, which may enable a U.S. BLA submission depending on outcomes.
Longeveron (NASDAQ: LGVN) announced the U.S. FDA has granted a Type C meeting at the end of March 2026 to align on clinical efficacy endpoints and the statistical analysis plan to support a potential BLA for laromestrocel (LOMECEL-B) in Hypoplastic Left Heart Syndrome (HLHS).
ELPIS II topline results are anticipated in Q3 2026. ELPIS II is a Phase 2b trial that enrolled 40 pediatric patients at 12 centers, conducted in collaboration with NHLBI through NIH grants. Laromestrocel holds Rare Pediatric Disease, Orphan Drug, and Fast Track designations.
Longeveron (NASDAQ: LGVN) was selected as a StartUp Health Alzheimer’s & Brain Health Moonshot company and will participate in StartUp Health Apollo House during JPM Healthcare Week in January 2026. Apollo House is a founders-and-funders networking summit focused on Health Moonshots for Alzheimer’s, Parkinson’s and related conditions, supported by champions including the Alzheimer’s Drug Discovery Foundation and Gates Ventures.
Longeveron said it will host meetings with institutional investors and potential partners during the week; investors may request meetings by contacting info@longeveron.com.